Please wait a minute...
Journal of Neurorestoratology  2018, Vol. 6 Issue (1): 88-92    doi: 10.26599/JNR.2018.9040007
Review Article     
Optogenetics to restore neural circuit function in Parkinson’s disease
Hyung Ho Yoon, Joongkee Min, Sang Ryong Jeon(✉)
Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea
Download: PDF (31911 KB)      HTML
Export: BibTeX | EndNote (RIS)      


Deep brain stimulation surgery has been performed in various movement disorders and psychiatric diseases. However, electrical stimulation may unexpectedly affect other types of adjacent neurons outside of the target area. Recently, optogenetics has provided the opportunity to modulate specific target neurons. Since this novel technique can individually control specific neurons in freely moving animals, it could be proposed to restore neural circuit function to related diseases, such as affective disorders, Huntington’s disease (HD), and Parkinson’s disease (PD). Herein, we discuss how optogenetics works as a treatment for Parkinson’s disease and other neural circuit dysfunctions.

Key wordsdeep brain stimulation      optogenetics      neural circuit      Parkinson disease     
Received: 09 July 2018      Published: 09 November 2018
Corresponding Authors: Sang Ryong Jeon   
About author: §These authors contributed equally to this work.
Cite this article:

Hyung Ho Yoon, Joongkee Min, Sang Ryong Jeon. Optogenetics to restore neural circuit function in Parkinson’s disease. Journal of Neurorestoratology, 2018, 6: 88-92.

URL:     OR

Fig.?1A use of Cre transgenic mouse for targeting. A combination of specific cell type Cre mice and stereotactic viral injection can induce optogene expression in specific cell type.
Fig.?2Behavioral tests. (a) Stepping test is a method to evaluate motor function of forelimbs. (b) Cylinder test can indicate the preference of either forelimb. (c) Drug induced rotation test can assess the degree of asymmetrical dopaminergic release.
[1]   Hague S, Klaffke S, Bandmann O. Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2005, 76(8):1058-1063.
[2]   Hedlund E, Perlmann T. Neuronal cell replacement in Parkinson’s disease. J Intern Med. Oct 2009, 266(4):358-371.
[3]   Fraix V, Pollak P, Van Blercom N, et al. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson’s disease. Neurology. 2000, 55(12):1921-1923.
[4]   Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010, 362(22):2077-2091.
[5]   Aravanis AM, Wang LP, Zhang F, et al. An optical neural interface: in vivo control of rodent motor cortex with integrated fiberoptic and optogenetic technology. Journal of neural engineering. 2007, 4(3):S143-156.
[6]   Larson PS. Deep brain stimulation for movement disorders. Neurotherapeutics. 2014, 11(3):465-474.
[7]   Yizhar O, Fenno LE, Davidson TJ, et al. Optogenetics in neural systems. Neuron. 2011, 71(1):9-34.
[8]   Deisseroth K. Optogenetics. Nature methods. 2011, 8(1):26-29.
[9]   Gradinaru V, Thompson KR, Zhang F, et al. Targeting and readout strategies for fast optical neural control in vitro and in vivo. The Journal of Neuroscience. 2007, 27(52):14231-14238.
[10]   Boyden ES, Zhang F, Bamberg E, et al. Millisecond- timescale, genetically targeted optical control of neural activity. Nature neuroscience. 2005, 8(9):1263-1268.
[11]   Monahan PE, Jooss K, Sands MS. Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opin Drug Saf. 2002, 1(1):79-91.
[12]   Connolly JB. Lentiviruses in gene therapy clinical research. Gene therapy. 2002, 9(24):1730-1734.
[13]   Kato T, Kasahara T, Kubota-Sakashita M, et al. Animal models of recurrent or bipolar depression. Neuroscience. 2016, 321:189-196.
[14]   Paille V, Henry V, Lescaudron L, et al. Rat model of Parkinson’s disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov Disord. 2007, 22(4):533-539.
[15]   Yoon HH, Park JH, Kim YH, et al. Optogenetic Inactivation of the Subthalamic Nucleus Improves Forelimb Akinesia in a Rat Model of Parkinson Disease. Neurosurgery. 2014, 74(5):533-541.
[16]   Schallert T, Fleming SM, Leasure JL, et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology. 2000, 39(5):777-787.
[17]   Zrinzo L, Yoshida F, Hariz MI, et al. Clinical safety of brain magnetic resonance imaging with implanted deep brain stimulation hardware: Large case series and review of the literature. World neurosurgery. 2011, 76(1–2):164-172.
[18]   Aristieta A, Azkona G, Sagarduy A, et al. The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats. PloS one. 2012, 7(8):e42652.
[19]   Wichmann T, Dostrovsky JO. Pathological basal ganglia activity in movement disorders. Neuroscience. 2011, 198:232-244.
[20]   Sgambato-Faure V, Cenci MA. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Progress in neurobiology. 2012, 96(1):69-86.
[21]   Yoon HH, Min J, Hwang E, et al. Optogenetic inhibition of the subthalamic nucleus reduces levodopa-induced dyskinesias in a rat model of Parkinson's disease. Stereotact Funct Neurosurg. 2016, 94(1):41-53.
[22]   Zhou L, Liu MZ, Li Q, et al. Organization of functional long-range circuits controlling the activity of serotonergic neurons in the dorsal raphe nucleus. Cell Rep. 2017, 20(8):1991-1993.
[1] Jingchao Lu, Zhaohai Feng, Xin Shi, Lei Jiang, Yujun Hao. Correlation between programmed stimulation parameters and their efficacy after deep brain electrode implantation for Parkinson’s disease[J]. Journal of Neurorestoratology, 2020, 8(1): 53-59.